Characterization of a CD40-dominant inhibitory receptor mutant

Journal of Immunology

Volumn 167, Issue 11, 2001, Pages 6388-6393

  Mehl, A M ^a   Jones, M ^a   Rowe, M ^a   Brennan, P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 INHIBITORY RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR PROTEIN; LATENT MEMBRANE PROTEIN 1; MUTANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL SURVIVAL; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035576001     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.11.6388     Document Type: Article

References (46)

1. The CD40/CD154 receptor/ligand dyad
2. Identification of TRAF6, a novel tumor necrosis factor receptor- associated factor protein that mediates signaling from an amino- terminal domain of the CD40 cytoplasmic region
3. Involvement of CRAFI, a relative of TRAF, in CD40 signaling
4. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor
5. A novel RING finger protein interacts with the cytoplasmic domain of CD40
6. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40
7. T cell-dependent induction of NF-kappa B in B cells
8. Induction of the transcription factors NF-κB, AP-1 and NF-AT during B cell stimulation through the CD40 receptor
9. Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells
10. Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40
11. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily
12. Ligation of CD40 on fibroblasts induces CD54 (1CAM-1) and CD106 (VCAM- 1) up-regulation and IL-6 production and proliferation
13. Epstein-Bart virus-encoded LMPI and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor- associated factors
14. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
15. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection
16. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytore-ductive host treatment
17. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
18. Three pathways of Epstein-Barr virus gene activation from EBNAI- positive latency in B lymphocytes
19. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75)
20. Signal transduction through the T cell receptor-CD3 complex: Evidence for heterogeneity in receptor coupling
21. Activation of human dendritic cells through CD40 cross-linking
22. Cutting edge: Human B cell function is regulated by interaction with soluble CD14. Opposite effects on IgGl and IgE production
23. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis
24. Two differently regulated nuclear factor KB activation pathways triggered by the cytoplasmic tail of CD40
25. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death
26. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein I
27. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain
28. Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions
29. Epstein-Barr virus: LMPI masquerades as an active receptor
30. The Epstein-Barr virus oncogene product latent membrane protein I engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB
31. Mechanism of action of a novel latent membrane protein-1 dominant negative
32. Transmembrane signals generated through MHC class II, CD19, CD20. CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway
33. Specificities of CD40 signaling: Involvement of TRAF2 in CD40-induced NF-κB activation and intercellular adhesion molecule-1 up-regulation
34. Cellular and molecular parameters in human renal allograft rejection
35. The structural basis for the recognition of diverse receptor sequences by TRAF2
36. Lymphotoxin-β receptor signaling complex: Role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor κB
37. Structural basis for self-association and receptor recognition of human TRAF2
38. Crystallographic analysis of CD40 recognition and signaling by human TRAF2
39. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
40. Tumor necrosis factor receptor signaling: A dominant negative mutation suppresses the activation of the 55-κDa tumor necrosis factor receptor
41. Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor κB to activate transcription
42. The CD40 pathway in allograft rejection, acceptance, and tolerance
43. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long-term engraftment and tolerance in stringent transplant models
44. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A
45. Development of adenovirus vectors encoding rat complement regulators for use in therapy in rodent models of inflammatory diseases
46. Expression in transgenic mice of dominant interfering Fas mutations: A model for human autoimmune lymphoproliferative syndrome